Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

DSpace/Manakin Repository

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells

Citable link to this page

 

 
Title: Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
Author: Lub, Susanne; Maes, Anke; Maes, Ken; De Veirman, Kim; De Bruyne, Elke; Menu, Eline; Fostier, Karel; Kassambara, Alboukadel; Moreaux, Jérôme; Hose, Dirk; Leleu, Xavier; King, Randall W.; Vanderkerken, Karin; Van Valckenborgh, Els

Note: Order does not necessarily reflect citation order of authors.

Citation: Lub, S., A. Maes, K. Maes, K. De Veirman, E. De Bruyne, E. Menu, K. Fostier, et al. 2016. “Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.” Oncotarget 7 (4): 4062-4076. doi:10.18632/oncotarget.6768. http://dx.doi.org/10.18632/oncotarget.6768.
Full Text & Related Files:
Abstract: The anaphase promoting complex/cyclosome (APC/C) is an ubiquitin ligase involved in cell cycle. During the metaphase-anaphase transition the APC/C is activated by Cdc20. The aim of this study is to elucidate the importance and therapeutic potential of APC/C and its co-activator Cdc20 in multiple myeloma (MM). Gene expression analysis revealed that Cdc20 was expressed at higher levels in gene expression-based high-risk MM patients. Moreover, high Cdc20 expression correlated with poor prognosis. Treatment of human myeloma cell lines with proTAME, an APC/C inhibitor, resulted in an accumulation of APC/CCdc20 substrate cyclin B1 and an accumulation of cells in metaphase. Moreover we observed a significant dose-dependent decrease in viability and increase in apoptosis in MM cells upon proTAME treatment. The induction of apoptosis was accompanied with caspase 3, 8, 9 and PARP cleavage. A similar metaphase arrest and induction of apoptosis were obtained with specific knockdown of Cdc20. In addition, we demonstrated the accumulation of Bim was partially responsible for the observed cell death. Combining proTAME with another APC/C inhibitor apcin or the alkylating agent melphalan resulted in enhanced anti-MM activity. This study suggests that the APC/C and its co-activator Cdc20 could be a new and promising target especially in high-risk MM patients.
Published Version: doi:10.18632/oncotarget.6768
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826190/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:27320358
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters